Unlike statins, antihypertensives, anticoagulants, and other critical therapies, antiplatelet medications are given with the assumption that all patients respond equally, but they do not.

One out of every three patients may not be responding adequately to their antiplatelet therapy.1
Numerous factors may contribute to inadequate response, including2
  • Drug interactions (e.g. Proton Pump Inhibitors)
  • Genetic polymorphisms (e.g. CYP2C19)
  • Pre-existing health conditions (e.g. Diabetes)
  • Non-compliance



Patients who are not responding adequately to their antiplatelet therapy may be at approximately 5 to 10 times greater risk of heart attack, stent thrombosis and death.5-8





It is important to assess your patients’ response to their antiplatelet medications.

Therefore, it has become more important to assess your patients’ response to their antiplatelet medications.

Backed by numerous peer-reviewed studies that demonstrate clinical utility and analytical performance, the VerifyNow System provides you with an easy, rapid and proven solution to help assess your patient’s response to the following antiplatelet medications:
  • - P2Y12 inhibitors (i.e., clopidogrel/Plavix®, prasugrel/Effient®, ticlopidine/Ticlid®)
  • - Aspirin (including low-dose)
  • - GP llb/llla inhibitors (i.e., abciximab/ReoPro®, eptifibatide/ Integrilin®)



  • Dupont, AG. et al. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009 May;124(1):6-13.
  • Maree, AO. et al. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-2207.
  • Hochholzer W, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564.
  • Serebruany, VL. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246-51.
  • Patti, G. et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008; 52:1128–33.
  • Marcucci, R. et al. Cardiovascular death and nonfatal myocardial Infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-Month follow-Up. Circulation. 2009;119(2):237-42.
  • Cuissett, T. et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol;2008 Jun 15;101(12):1700-3.
  • Price, MJ. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000.
  • Buonamici P, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312-7.